Variable | Odds Ratio | 95% Confidence Interval | P-value |
---|---|---|---|
Univariable analysis | Â | Â | Â |
Age (continuous) | 1.006 | 1.005–1.008 | < 0.0001 |
Sex (female vs. male) | 0.886 | 0.864–0.908 | < 0.0001 |
Baseline A1C (continuous) | 1.237 | 1.225–1.249 | < 0.0001 |
Complication (short vs. none) | 1.691 | 1.640–1.744 | < 0.0001 |
Complication (long vs. none) | 1.565 | 1.504–1.629 | < 0.0001 |
Complication (Both short and long vs. none) | 4.608 | 4.267–4.976 | < 0.0001 |
Metro status (non-metro vs. metro) | 1.110 | 1.072–1.151 | < 0.0001 |
Charlson Comorbidity Index (continuous) | 1.203 | 1.187–1.218 | < 0.0001 |
Multivariable analysis | Â | Â | Â |
Age (continuous) | 1.002 | 1.000–1.003 | 0.0397 |
Sex (female vs. male) | 0.976 | 0.942–1.011 | 0.1717 |
Baseline A1C (continuous) | 1.188 | 1.176–1.200 | < 0.0001 |
Complication (short vs. none) | 1.562 | 1.496–1.631 | < 0.0001 |
Complication (long vs. none) | 1.497 | 1.414–1.584 | < 0.0001 |
Complication (Both short and long vs. none) | 3.545 | 3.185–3.944 | < 0.0001 |
Metro status (non-metro vs. metro) | 1.105 | 1.046–1.167 | 0.0004 |
Charlson Comorbidity Index (continuous) | 1.133 | 1.113–1.154 | < 0.0001 |